Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Chinese PLA General Hospital
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Ossium Health, Inc.
Intima Bioscience, Inc.
City of Hope Medical Center
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Chinese PLA General Hospital
Herlev Hospital
Juventas Cell Therapy Ltd.
Chinese PLA General Hospital
Chinese PLA General Hospital
Chinese PLA General Hospital
Thomas Jefferson University
Chinese PLA General Hospital
GeoVax, Inc.
Celularity Incorporated
Therapeutic Advances in Childhood Leukemia Consortium
Herlev Hospital
Chinese PLA General Hospital
M.D. Anderson Cancer Center
Baptist Health South Florida
M.D. Anderson Cancer Center
Mustang Bio
Arog Pharmaceuticals, Inc.
Columbia University
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Washington University School of Medicine
Arog Pharmaceuticals, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Children's Oncology Group
Herlev Hospital
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
St. Petersburg State Pavlov Medical University
M.D. Anderson Cancer Center